Member Info for Retireby40

Well Arsenal as their current run rate they’ll have cash for over 18 months and given the increased opportunities and customers revenue should increase so that 18 months of cash should be even more in fact they only burnt £1.1m in July and August so at that rate it would be 24 months and that’s without an increase in revenue. Looking strong here and with fewer things in production even more opportunities lay ahead in the short term.

· Cash and cash equivalents of £14.4m (30 June 2019 £9.2m), up 57% following the 2019 fundraise, net of trading losses. Gross cash balance at end August 2020 is £13.3m.

· Cash consumption significantly reduced to £4.5m (30 June 2019 £5.9m), down 24%, through proactive cost management while the volume of activity increased

Ha, one can hope and I’d change it to retired by 43. That said it would still be by 40 albeit that wasn’t the intention when I stopped work!

When I started posting here I was younger than 40 but am now 42 and as it happens quit a job I’d been in for 14 years with some cash rather then equity I was due if I stayed (a small private business) just before my 40th b’day, bizarrely that’s how it panned out.

I may or may not go back to work but I’m less bored than I was when I used to have a day working from home in my old job and found that tricky.

Anyway, I’ve managed to do well (on paper) in SKIN MWG AVCT SNG and MIRI in particular so I hope to not work again!

I try hope and expect the takeover to go through and as well as the interim RNS, takeover news we should have news on the real-time prototype as this is expected end of the Q. A lot to look forward to I believe.

Here's some information about the body that will be giving the £50m funding...

https://www.nihr.ac.uk/documents/artificial-intelligence-in-health-and-care-award-2020-guidance-for-phase-4/24006#The_AI_in_Health_and_Care_Award

Through the Phase 4 AI Award, the AAC Delivery Team will identify medium stage AI technologies that have market authorisation but insufficient evidence to merit large-scale commissioning or deployment (Figure 2). Award amounts are uncapped, awards are per technology, with an indicative budget of £5-10m in the first year. Applicants for Phase 4 apply through the AI Award Call for Applications.

The AAC Delivery Team will facilitate initial systems adoption of the AI technologies into the NHS and evaluate the AI technology within clinical or operational pathways to determine efficacy or accuracy, and clinical and economic impact. Phase 4 will support the development, testing and evaluation of suitable AI technology in health and social care by:

Selecting and funding promising products: Working with leading experts across the NHS to identify innovations that are of value to stakeholders and align with our strategic aims (as outlined in the NHS Long Term Plan). A themed-approach may be taken where more than one supplier of an AI technology exists: in this instance multiple suppliers of the technology may be awarded a grant and supported by the AI Award to develop, for example suppliers of a screening AI technology. Key areas of focus include:
i. Diagnosis;
ii. Screening;
iii. Decision support and;
iv. Improving system efficiency.

Providing implementation support: Working with AHSNs, our existing partners in the regions, as well as with leading experts and specialists such as CIOs and CCIOs we will identify NHS or social care sites that are ready for adoption of the selected AI products. Funding and support will be provided to a handful of sites per technology to support local testing, removing barriers to adoption and facilitating changes in clinical pathways where appropriate, including:
v. Funding for staff in adopting sites to undertake the training and change management required for implementation of these technologies;
vi. Support on project set up, programme management and procurement from the AAC Delivery Team;
vii.Specialist support from NHSX’s AI Lab SWAT team in areas such as information governance and interoperability.
Developing a plan for long-term sustainability: The AAC Delivery Team will support the development, testing and evaluation of innovative commercial models and reimbursement mechanisms that:
viii. Incentivise initial uptake of the innovation;
ix. Capture the efficiencies associated with adoption of the innovation and;
x. Are cost-neutral over a number of years, but not necessarily in-year.
These approaches will be trialled as part of the AI Award, preparing the reimbursement system to accommodate and incentivise use of these products and other innovations.

Here's some information about the body that will be giving the £50m funding...

https://www.nihr.ac.uk/documents/artificial-intelligence-in-health-and-care-award-2020-guidance-for-phase-4/24006#The_AI_in_Health_and_Care_Award

Through the Phase 4 AI Award, the AAC Delivery Team will identify medium stage AI technologies that have market authorisation but insufficient evidence to merit large-scale commissioning or deployment (Figure 2). Award amounts are uncapped, awards are per technology, with an indicative budget of £5-10m in the first year. Applicants for Phase 4 apply through the AI Award Call for Applications.

The AAC Delivery Team will facilitate initial systems adoption of the AI technologies into the NHS and evaluate the AI technology within clinical or operational pathways to determine efficacy or accuracy, and clinical and economic impact. Phase 4 will support the development, testing and evaluation of suitable AI technology in health and social care by:

Selecting and funding promising products: Working with leading experts across the NHS to identify innovations that are of value to stakeholders and align with our strategic aims (as outlined in the NHS Long Term Plan). A themed-approach may be taken where more than one supplier of an AI technology exists: in this instance multiple suppliers of the technology may be awarded a grant and supported by the AI Award to develop, for example suppliers of a screening AI technology. Key areas of focus include:
i. Diagnosis;
ii. Screening;
iii. Decision support and;
iv. Improving system efficiency.

Providing implementation support: Working with AHSNs, our existing partners in the regions, as well as with leading experts and specialists such as CIOs and CCIOs we will identify NHS or social care sites that are ready for adoption of the selected AI products. Funding and support will be provided to a handful of sites per technology to support local testing, removing barriers to adoption and facilitating changes in clinical pathways where appropriate, including:
v. Funding for staff in adopting sites to undertake the training and change management required for implementation of these technologies;
vi. Support on project set up, programme management and procurement from the AAC Delivery Team;
vii.Specialist support from NHSX’s AI Lab SWAT team in areas such as information governance and interoperability.
Developing a plan for long-term sustainability: The AAC Delivery Team will support the development, testing and evaluation of innovative commercial models and reimbursement mechanisms that:
viii. Incentivise initial uptake of the innovation;
ix. Capture the efficiencies associated with adoption of the innovation and;
x. Are cost-neutral over a number of years, but not necessarily in-year.
These approaches will be trialled as part of the AI Award, preparing the reimbursement system to accommodate and incentivise use of these products and other innovations.

If Han**** was referring to us surely an RNS would be published? Would it only be material if something had been signed re gov money As let’s face it the gov does not keep its promises.

That would be amazing if the case so hopefully even email confirmation from Han****/Rishi and we get an RNS.

From advfn -

Both PLCs look undervalued and I’d argue SKIN even more so. The MWG and its BoD and need to look after their shareholders and think it a good deal. I hold more MWG than SKIN and am happy with the deal. They’ve worked closely for 6 months or so and the synergies are obvious and seemingly stronger together.
If the real-time solution works for COVID and other pathogens/contaminants it is massive and remember the driving force is SKIN and AI. MWG and its superb units are a route to market and there are other cos out there SKIN could partner but I guess that’s taken off the table is the takeover happens so they can dominate.

From nicebut on the guild -

What did Dr Ditchek say:

'we will be hearing alot more about this drug'.

`Synairgen is in discussions with a number of regulatory agencies worldwide to establish the regulatory route to the approval of SNG001 as a treatment for COVID-19.`

With peer review due as well as full data being released, safety seemingly a non issue and infections on the up all over an effective therapy is needed ASAP and better still one that can be used both at hospital and at home before hospitalisation.

I have done the same. I did so on the RNS day as the gao between the two was bigger.

Looking forward to the takeover happening, consolidation followed by positive RNSs and the big one re real-time monitoring.

I don’t think we should assume that will be sold as it’s generating income and they’re going the partnership route so don’t need to spend as much money.

As far as getting it on the cheap getting 1 new group share seems fair enough to me and given the AI potential with real-time monitoring and much more there’s an argument to say SKIN is also undervalued so MWG is getting a decent deal. Definitely stronger together and I’ll be voting for the deal.

It’s simple, if a buy is executed below mid price it’s reported as a sell and if a sell is above mid it’ll go down as a buy.

A vaccine won’t be readily available for probably a year. I’d wager at most 50% of the population would take it and remember vaccines tend to be around 60% effective. Therapies needed for a long time yet as well as antigen testing.

Great interferon beta is being discussed in the US and even better we are attracting US investors which reinforces confidence but more importantly will be more palatable for the US to spend money whether it be licensing/trials etc.

Surely news on COPD this week swiftly followed by news on COVID.

Ha, not the kind of exposure I’d usually go for either!

https://twitter.com/erictopol/status/1302308778084167680?s=21

**** off charlietrader spam bull****. Do not click link.

GB is on holiday and hopefully not looking in here too much. I’m sure his other half will be losing patience.

Sure he needs to recharge before a very busy end to Q3 as well as a transformational Q4. RNSs to look forward to - interim results, confirmation of takeover, team-time prototype being tested with the live virus in a Level 3 lab ahead of validation, OEMs signed as I’m sure demand will be massive and partnerships will be key to meeting demand. That’s in the near term then we have many possible RNSs re Labskin, AMBC wins for MWG and much more.

The share price will settle once takeover confirmed and a market cap of £50m plus will be great and as mentioned get on many fund managers radar. Exciting times.

Why does GB need to comment when it’s clear as day in the RNS I posted yesterday. The NOMAD of both PLCs and BoDs would’ve signed off the respective RNSs. I suggest all read the RNSs and twice!

He/she obviously has a serious grudge and if they sent info not on the public domain I assume they know someone who was connected to the co, maybe worked there and given the reduction in staff have a bee in their bonnet.

Who knows but their knowledge of SKIN is more than a little poor and making those inaccurate statements is bang out of line. I’ll leave it there but they have a clear agenda.

He’s suggesting they’ve lied in regulated RNSs, both SKIN and MWG. The NOMADs would be in trouble too if this was the case which it clearly isn’t. He should have the decency to retract the ludicrous accusation.